VANCENASE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANCENASE (VANCENASE).
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, leading to inhibition of inflammatory mediators such as cytokines and prostaglandins.
| Metabolism | Hepatic via cytochrome P450 3A4 (CYP3A4) to active metabolite beclomethasone-17-monopropionate, which is further metabolized. |
| Excretion | Primarily hepatic metabolism; excreted in urine (approximately 10% as unchanged drug and metabolites) and feces (approximately 80% as metabolites). |
| Half-life | Terminal elimination half-life is approximately 3.5 hours after intranasal administration. Clinically, this short half-life supports twice-daily dosing for sustained effect. |
| Protein binding | Approximately 87% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 2.6 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Intranasal: approximately 50% systemic bioavailability due to direct absorption across nasal mucosa and some gastrointestinal absorption from swallowed portion. Oral: low and variable (approximately 20%) due to first-pass metabolism. |
| Onset of Action | Intranasal: clinical effect may be observed within 12-24 hours, with maximal benefit often after several days of regular use. |
| Duration of Action | Duration of action is approximately 12-24 hours after intranasal administration, supporting twice-daily dosing. Effects are maintained with regular use. |
| Molecular Weight | 521.0 Da |
1-2 inhalations (50-100 mcg) per nostril twice daily (100-200 mcg/day total).
| Dosage form | AEROSOL, METERED |
| Renal impairment | No adjustment required for renal impairment. |
| Liver impairment | No adjustment required for hepatic impairment. |
| Pediatric use | Age 6-11 years: 1 inhalation (50 mcg) per nostril once daily, may increase to twice daily if needed. Age 12-17 years: same as adult. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential increased sensitivity. |
| 1st trimester | Limited human data; animal studies have shown teratogenic effects at high doses. Use only if potential benefit justifies risk. |
| 2nd trimester | No well-controlled studies; minimal systemic absorption due to topical application. However, caution is advised. |
| 3rd trimester | May be used if clearly needed; no known risk of fetal harm from topical intranasal corticosteroids. |
Clinical note
Comprehensive clinical and safety monograph for VANCENASE (VANCENASE).
| Placental transfer | Beclomethasone dipropionate crosses placenta; extent unknown but likely minimal due to low systemic bioavailability after intranasal use. |
| Breastfeeding | Beclomethasone dipropionate is excreted in breast milk in trace amounts after topical application; unlikely to affect nursing infant. Use with caution. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to beclomethasone dipropionate or any component of the formulationUntreated localized infection involving the nasal mucosa
| Precautions | Nasal irritation, epistaxis, and nasal septal perforation, Potential for systemic corticosteroid effects with prolonged use (e.g., adrenal suppression, growth retardation in children), Avoid use in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections, Use with caution in patients with recent nasal surgery or trauma |
| Food/Dietary | No significant food interactions. Grapefruit and grapefruit juice do not interact with intranasal beclomethasone. Avoid alcohol if it exacerbates nasal congestion. |
Loading safety data…
| Lactation Rating |
| L2 (Probably Compatible) |
| Teratogenic Risk | VANCENASE (beclomethasone dipropionate) is an inhaled corticosteroid. In animal studies, corticosteroids have been shown to be teratogenic. However, inhaled corticosteroids at recommended doses are not associated with a significant increase in congenital malformations. First trimester: Limited data, but no clear evidence of increased risk. Second and third trimesters: Risk of intrauterine growth restriction (IUGR) with prolonged high-dose systemic exposure; inhaled doses minimize systemic absorption. |
| Fetal Monitoring | Monitor maternal asthma control, fetal growth (serial ultrasounds for IUGR if high-dose or prolonged systemic use), and maternal blood glucose (corticosteroids may increase insulin resistance). Assess for signs of adrenal suppression in mother if used long-term at high doses. |
| Fertility Effects | No known adverse effects on human fertility. In animal studies, corticosteroids may impair fertility at high systemic doses, but inhaled beclomethasone at therapeutic doses is unlikely to affect fertility. |
| Clinical Pearls | VANCENASE (beclomethasone dipropionate) is an intranasal corticosteroid. Onset of action is not immediate; regular use for several days to weeks is needed for full effect. Priming with 6-7 sprays after prolonged non-use is required. Shake well before use. Avoid spraying directly onto the nasal septum to prevent irritation and bleeding. May cause epistaxis and nasal septal perforation with long-term use. Monitor for signs of adrenal suppression when used at higher than recommended doses. |
| Patient Advice | Use regularly as prescribed, not for immediate relief. · Shake the canister gently before each use. · Prime the pump by spraying 6-7 times into the air if not used for more than 1 week. · Blow nose gently before each use to clear nasal passages. · Insert nozzle into nostril, aim away from septum, and spray while breathing gently. · Do not use more than 2 sprays per nostril daily. · Rinse nozzle with warm water and dry after each use to prevent clogging. · Report persistent nosebleeds, severe nasal irritation, or signs of infection. · Do not stop abruptly; taper as directed. · Keep out of reach of children. |